對稱N,N-二甲基精氨酸
|
|
|
- CAS號:
- 30344-00-4
- 英文名:
- N,N'-Dimethylarginine
- 英文別名:
- SDMA-d6;SDMA, 10 mM in DMSO;N,N'-Dimethylarginine;H-Arg(Me, Me)-OH (sym);NG'-Dimethyl-L-arginine;Symmetric dimethylarginine;Nω,N'ω-dimethyl-L-arginine;NG,NG’-Dimethy-L-arginine-d6;L-Arg(Me, Me)-OH (syMMetrical);L-Arg(Me, Me)-OH (asyMMetrical)
- 中文名:
- 對稱N,N-二甲基精氨酸
- 中文別名:
- 對稱二甲基精氨酸;對稱性二甲基精氨酸;N,N-二甲基精氨酸;對稱N,N-二甲基精氨酸;N,N-二甲基精氨酸(精氨酸雜質(zhì)23);對稱N,N'-二甲基精氨酸溶液,100PPM;對稱N,N-二甲基精氨酸,10 MM DMSO 溶液;(S)-2-氨基-5-((雙(甲基氨基)亞甲基)氨基)戊酸;(2S)-2-氨基-5-[(N,N'-二甲基甲脒基)氨基]戊酸;NG,NG'-二甲基-L-精氨酸二(對羥基偶氮苯-P'-磺酸鹽)鹽
- CBNumber:
- CB91236269
- 分子式:
- C8H18N4O2
- 分子量:
- 202.25
- MOL File:
- 30344-00-4.mol
|
|
|
對稱N,N-二甲基精氨酸化學(xué)性質(zhì)
-
沸點:
-
353.5±52.0 °C(Predicted)
-
|
-
密度:
-
1.22±0.1 g/cm3(Predicted)
-
|
-
儲存條件:
-
Keep in dark place,Inert atmosphere,Room temperature
-
|
-
溶解度:
-
DMSO : 50 mg/mL (247.22 mM; ultrasonic and adjust pH to 3 with 1M HCl)
-
|
-
酸度系數(shù)(pKa):
-
2.48±0.24(Predicted)
-
|
-
形態(tài):
-
Orange powder.
-
|
-
顏色:
-
White to off-white
-
|
-
穩(wěn)定性:
-
Very Hygroscopic
-
|
對稱N,N-二甲基精氨酸性質(zhì)、用途與生產(chǎn)工藝
SMDA (symmetric dimethylarginine)是精氨酸的甲基化形式，存在于所有的有核細(xì)胞中，在蛋白質(zhì)水解后被釋放到循環(huán)體統(tǒng)中，通過腎臟排泄，在人、犬類和貓中與腎小球濾過率相關(guān)。
|
Human Endogenous Metabolite
|
SDMA is the structural isomer of the cardiovascular risk marker asymmetric dimethylarginine, as an endogenous marker of renal function. SDMA does not directly inhibit NOS but is a competitor of arginine transport. SDMA is primarily eliminated by renal excretion and is a promising endogenous marker of glomerular filtration rate. SDMA inhibits dose dependently the NO synthesis in intact endothelial cells, whereas it has no effect on protein expression of NOS. SDMA is involved in the inflammatory process of chronic kidney disease, activating NF-κB and resulting in enhanced expression of IL-6 and TNF-α.
SDMA is highly stable in serum and plasma, and the assay demonstrates excellent analytical performance. In unaffected dogs, SDMA remains unchanged whereas in affected dogs, SDMA increases during disease progression, correlating strongly with an increase in sCr and decrease in GFR. Chronic SDMA infusion leads to a significant increase of SDMA levels in mice, but the GFR did not change at 4 weeks. No histological changes are observed, particularly no effect on fibrosis or endothelias nitric oxide synthase expression. There is neither an effect of SDMA on systolic blood pressure nor on ejection fraction.
對稱N,N-二甲基精氨酸
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2025/02/08 | HY-101410S | 對稱N,N-二甲基精氨酸
SDMA-d6 | 30344-00-4 | 1 mg | 5850元 |
| 2025/02/05 | S5838 | 對稱N,N-二甲基精氨酸
SDMA | 30344-00-4 | 5mg | 795.38元 |
30344-00-4, 對稱N,N-二甲基精氨酸 相關(guān)搜索:
- Pharmaceuticals
- Isotope Labeled Compounds
- Intermediates & Fine Chemicals
- Amino Acids & Derivatives
- Isotope Labelled Compounds
- 抑制劑
- 代謝物
- 雜質(zhì)
- 氨基酸
- 非天然氨基酸
- C8H12D6N4O2
- 30135-93-6
- 對稱N,N-二甲基精氨酸,10 MM DMSO 溶液
- NG,NG'-二甲基-L-精氨酸二(對羥基偶氮苯-P'-磺酸鹽)鹽
- 對稱二甲基精氨酸
- N,N-二甲基精氨酸(精氨酸雜質(zhì)23)
- (2S)-2-氨基-5-[(N,N'-二甲基甲脒基)氨基]戊酸
- N,N-二甲基精氨酸
- (S)-2-氨基-5-((雙(甲基氨基)亞甲基)氨基)戊酸
- 對稱性二甲基精氨酸
- NG,NG′-二甲基-L-精氨酸二(對羥基偶氮苯-P'-磺酸鹽)鹽
- 對稱N,N-二甲基精氨酸
- 對稱N,N'-二甲基精氨酸溶液,100PPM
- 30344-00-4
- N,N'-Dimethylarginine
- SDMA, 10 mM in DMSO
- Symmetric dimethylarginine（SDMA）
- (2S)-2-amino-5-[(N,N-dimethylcarbamimidoyl)amino]pentanoic
- inhibit,Inhibitor,Endogenous Metabolite,SDMA
- H-Arg(Me, Me)-OH (sym)
- N,N'-Dimethylarginine USP/EP/BP
- L-Ornithine,N5-[(methylamino)(methylimino)methyl]-
- L-Arg(Me,Me)-OH(symmetrical), >97%
- Nω,N'ω-dimethyl-L-arginine
- NG'-Dimethyl-L-arginine
- NG,NG'-Dimethy-L-arginine Solution, 100ppm
- (S)-2-Amino-5-((bis(methylamino)methylene)amino)pentanoic acid
- SDMA-d6
- NG,NG’-Dimethy-L-arginine-d6
- N5-[Bis(methylamino)methylene]-L-ornithine-d6
- N5-[(Dimethylamino)iminomethyl]-L-ornithine-d6
- Symmetric dimethylarginine
- L-Arg(Me, Me)-OH (asyMMetrical)
- L-Arg(Me, Me)-OH (syMMetrical)
- (2S)-2-amino-5-[(N,N'-dimethylcarbamimidoyl)amino]pentanoic acid